Home

 

Link to COMPETE Clinical Trial

COMPETE.
Phase III Clinical Trial.

Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.

View details >>

Five employees about "Passion for Precision" at ITM.

See five employees talking about their work at ITM with five different views on “Passion for Precision”. A compilation.

Watch individual interviews >>

July 26, 2018

RadioMedix and ITM announce agreement for manufacturing of Ge-68/Ga-68 generators in U.S.

Full releases >>

July 09, 2018

Endocyte and ITM announce Long-Term Supply Agreement for no-carrier-added Lutetium-177

Full releases >>

July 06, 2018

Bruce Power joins forces with ITM to supply Lutetium-177 for cancer therapy

Full releases >>

Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...

Join the ITM Team >>